Elanco Animal Health Incorporated Common Stock vs Range Resources Corporation Common Stock — how do they compare? Elanco Animal Health Incorporated Common Stock trades at $22.68 (market cap $11.20B), while Range Resources Corporation Common Stock trades at $41.78 (market cap $9.93B). The key difference: Elanco Animal Health Incorporated Common Stock and Range Resources Corporation Common Stock are close in size by market cap, and Range Resources Corporation Common Stock pays a 0.94% dividend while Elanco Animal Health Incorporated Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Elanco Animal Health Incorporated Common Stock for 6 Days and Range Resources Corporation Common Stock for 0 Days on average.
| ELAN | RRC | |
|---|---|---|
Market Cap | $11.20B | $9.93B |
Volume | 3,345,224 | 2,413,752 |
Sector | Health | Energy |
52-Week High | $26.84 | $47.65 |
52-Week Low | $19.80 | $33.43 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $14.58B | $10.94B |
Dividend Yield | — | 0.94% |
Signals from Pluang's Aura AI — not financial advice
ELAN trades at $22.41, down 0.66% today, with a bearish technical signal from moving averages. The company reported a net loss of $232 million in 2025, though revenue grew to $4.72 billion. Recent earnings beats and a 71% analyst buy rating reflect optimism around new product launches like Zenrelia and deleveraging plans discussed at recent conferences.
The outlook hinges on execution of growth initiatives to achieve profitability. Upside exists if new products gain market share as projected, but risks include persistent losses, competitive pressures, and high debt. The consensus price target of $28.00 suggests 25% potential upside from current levels.
Range Resources (RRC) trades at $42.48, up 2.56% today, with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows solid fundamentals with a P/E of 11.73 and net income margin of 26.32%, while technical indicators signal neutral momentum near key resistance at $43. Recent institutional buying and positive analyst coverage (38.71% buy ratings) support the bullish case.
Outlook remains positive with Q3 2026 earnings expected at $0.776 per share and consensus price target of $44.00 offering 3.6% upside. Risks include energy price volatility and negative net cash flow of -$304M in 2025, though improved 2026 projections show operating cash flow growth to $1.4B.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Elanco develops medicines, vaccines, and other health products for pets and livestock. Its products address prevention and treatment of animal diseases.
Read more on ELAN →Range Resources Corporation is an independent natural gas and natural gas liquids producer operating in the Appalachian Basin, primarily the Marcellus Shale in Pennsylvania, handling drilling, completion, and gathering and transportation connections for its production.
Read more on RRC →